(2026). A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence. Dermatology and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence."
Dermatology and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence."
Dermatology and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.